COMMUNIQUÉS West-GlobeNewswire
-
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
14/07/2026 -
Dandy Unveils Polychromatic Shade™ to End the Trade-Off Between Dental Aesthetics and Affordability
14/07/2026 -
Visory Health Wins a Digital Health Award for Second Consecutive Year
14/07/2026 -
Cannara Announces a Long-Term International Cannabis Supply Agreement with Curaleaf International Limited
14/07/2026 -
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
14/07/2026 -
Axiom Biosciences Reports Positive Phase 1 Results for Investigational Stem Cell Therapy in Newborns with Severe Brain Injury
14/07/2026 -
SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)
14/07/2026 -
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
14/07/2026 -
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
14/07/2026 -
XOMA Royalty Announces Closing of Its Acquisition by Ligand
14/07/2026 -
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
14/07/2026 -
Verano Hosting Grand Opening Celebration of MÜV Bradfordville on Friday, July 17th, Elevating the Company’s Retail Footprint to 86 Florida Dispensaries and 163 Locations Nationwide
14/07/2026 -
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
14/07/2026 -
Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
14/07/2026 -
Aeroflow Sleep Donates to Beds for Kids and Project Sleep to Improve Sleep Health Equity
14/07/2026 -
MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and Dementia
14/07/2026 -
Adneuris Therapeutics Grants Exclusive License to Zhejiang Conba Pharmaceutical to Advance Cebranopadol in Greater China
14/07/2026 -
Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
14/07/2026 -
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
14/07/2026
Pages